Wegovy age approval: what the UK licence actually says

You're 17 and you're being told you have to wait, here's why

It is genuinely frustrating to be told a treatment exists, that it works, and that you cannot have it for another year or two because of your date of birth. That frustration is real, and it is worth being straight about the reason rather than just repeating a rule. The UK licence for Wegovy was granted to Novo Nordisk based on clinical trial data gathered in adult populations. NICE's recommendation for semaglutide for weight management, published in NICE technology appraisal TA875, specifies adults. The medicine has not been through the same regulatory evaluation in children or adolescents for this indication, so no prescriber in the UK can legitimately issue it to someone under 18. That is not a cautious interpretation of the rules, it is the rule. Once a person turns 18, the standard eligibility criteria apply: a BMI of 30 or above, or 27 or above alongside a weight-related condition, confirmed by a prescriber following a clinical assessment. Conditions that can qualify at the lower BMI threshold include high blood pressure, raised cholesterol, obstructive sleep apnoea, prediabetes and type 2 diabetes, among others.

What the licence covers once you reach 18

The semaglutide licence for weight management applies to any adult who meets the BMI and health criteria, with no upper age ceiling. The NHS medicines information for semaglutide confirms the adult-only framing. At 18, the clinical picture is assessed freshly: BMI is verified, relevant health conditions are considered, and any contraindications are checked. Contraindications that cut across all ages include a personal or family history of medullary thyroid carcinoma, MEN2, active pancreatitis, or pregnancy. Beyond those absolute bars, the prescriber weighs the individual picture. A 19-year-old with a BMI of 32 and well-controlled hypertension may well be suitable; a 23-year-old with a complex GI history may not be. Age clears one hurdle, the clinical review is the substantive one. The treatment schedule starts at 0.25 mg weekly, titrated gradually upward by the prescriber to the maintenance dose; the timeline of semaglutide's regulatory approvals helps explain why the titration schedule looks the way it does.

The 7.2 mg option and what it changes about the age picture

In April 2026 the MHRA approved a single-dose 7.2 mg Wegovy pen, a higher maintenance dose that reported around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide results. The age rules did not change with that approval: the 7.2 mg pen carries a BMI-30-or-above requirement and remains an adult-only medicine. If you are reading about this newer option and wondering whether it opens a different route, it does not. The UK approval history for Wegovy covers each regulatory milestone if you want the full sequence. What the 7.2 mg approval does change is the ceiling: adults who have worked through the titration schedule now have a higher maximum dose available, subject to their prescriber's judgement and clinical re-review. Availability of specific pen formats is confirmed at consultation, not before. For context on how Wegovy's cost compares to other options, the weight-loss treatment overview gives a straightforward comparison.

Under-18s and the clinical evidence gap

The absence of a paediatric licence is not an accident or an administrative lag. Clinical trial programmes for weight-management medicines in under-18s are a separate regulatory undertaking, with different ethical frameworks and different outcome measures. As of summer 2026, semaglutide has not received a UK or European paediatric weight-management indication. Some separate research exists in younger age groups for different formulations and different conditions, but none of it translates into a licensed weight-management route for under-18s in the UK. Families navigating weight management for teenagers should speak to a GP or paediatrician, who can refer to appropriate specialist services. If you are 18 or approaching it and want to understand the private consultation process, this page on sourcing Wegovy through a registered UK pharmacy explains what to expect. If you have a question that falls outside the standard eligibility checks, our team is reachable seven days a week. When you are ready to see whether you qualify, start a free consultation with our prescribers and a real clinician will review your case the same day.